Publications by authors named "Shereen H Aboul Naga"
Article Synopsis
- - The study investigates the effects of biologic therapy on children with juvenile idiopathic arthritis-associated uveitis (JIA-U) by analyzing data from 35 eyes over various follow-up periods.
- - Success rates for treatment outcomes showed 77% achieved stable/improved vision and 91% had reduced inflammation after 12 months, while long-term results indicated a peak in complete success at 18 months.
- - The conclusion highlights that biologic therapy is effective for managing JIA-U, especially in reducing reliance on systemic steroids and maintaining stable vision.
Article Synopsis
- Behçet's Disease (BD), also known as "The Silk Road Disease," is characterized by recurrent mouth and genital ulcers, along with uveitis, and is becoming prominent in clinics focused on ocular inflammatory diseases.
- * The review discusses the clinical features of BD, diagnostic strategies, and the emerging role of the human microbiome in its pathophysiology, particularly with findings from recent studies.
- * Advances in treatment options, including cytokine-blocking biologics and the impact of the COVID-19 pandemic on BD's management and morbidity, are also examined.
In the ophthalmological clinic, intravitreally applied antibodies or Fc-containing fusion proteins are frequently used, but the biology and pharmacokinetics of these therapeutics in the retina are not well understood. We have previously shown intracellular uptake of Fc-containing molecules in RPE cells. In this study, we investigated the involvement of Fc-receptors, both Fcγ-receptors and the neonatal Fc-receptor (FcRn) in the uptake and intracellular trafficking of the VEGF-antagonists bevacizumab, aflibercept and the anti-CD20 antibody rituximab in three different model systems, primary porcine RPE cells, ARPE-19 cells and porcine RPE/choroid explants.
View Article and Find Full Text PDFThe anti-VEGF antibody bevacizumab is widely used off-label for the treatment of various ocular diseases, most commonly in age-related macular degeneration and diabetic macular edema. Bevacizumab is able to penetrate the retina and is found in the choroid after intravitreal injection in a time dependent manner. It has previously been shown to be taken up by the retinal pigment epithelium (RPE).
View Article and Find Full Text PDF